NEWTOWN, Pa., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced two presentations relating to clinical trials of its most advance product candidate, rigosertib, at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, December 7-10, 2013. The presentations will include data on efficacy, tolerability, and dosing regimen from the Phase 2 study (ONTARGET) of oral rigosertib in transfusion-dependent, lower risk MDS patients and response, overall survival, and longer-term follow-up data from a Phase 1/2 trial of IV rigosertib in higher risk post-hypomethylating agent treated MDS and AML patients.
Details for the presentations are as follows:
Abstract #2745
Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses
| Date: | Sunday, December 8, 2013 |
| Time: | 6:30 PM - 8:30 PM |
| Session: | 633. Myelodysplastic Syndromes: Poster II |
| Location: | Ernest N. Morial Convention Center, Hall E |
| Presenter: | Azra Raza, MD, MDS Center, Columbia University Medical Center, New York, NY |
Abstract #1527
Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents
| Date: | Saturday, December 7, 2013 |
| Time: | 5:30 PM - 7:30 PM |
| Session: | 633. Myelodysplastic Syndromes: Poster I |
| Location: | Ernest N. Morial Convention Center, Hall E |
| Presenter: | Shyamala C. Navada, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com.